Goldman Sachs
RNA

Goldman Sachs’s Atrium Therapeutics RNA Stock Holding History

Goldman Sachs’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.17M Sell
310,341
-39,609
-11% -$517K ﹤0.01% 4045
2026
Q1 		$4.68M Buy
+349,950
New +$4.92M ﹤0.01% 3771

Other funds holding RNA

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs's RNA Position: Q2 2026 in Review

Goldman Sachs reduced its Atrium Therapeutics (RNA) stake by 11% in Q2 2026, selling an estimated $517K and leaving 310,341 shares worth $4.17M. The position accounts for ﹤0.01% of the portfolio, ranked #4045.

Goldman Sachs first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.68M in Q1 2026. 155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Goldman Sachs held 310,341 shares of Atrium Therapeutics worth $4.17M as of Q2 2026.
  • Goldman Sachs sold 39,609 Atrium Therapeutics shares in Q2 2026, an estimated $517K.
  • Atrium Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4045 holding.
  • Goldman Sachs first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Goldman Sachs's Atrium Therapeutics position peaked at $4.68M in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.